Form 424B3 - Prospectus [Rule 424(b)(3)]:
SEC Accession No. 0001628280-24-015671
Filing Date
2024-04-11
Accepted
2024-04-10 19:37:49
Documents
20

Document Format Files

Seq Description Document Type Size
1 424B3 lenztherapeutics424b3.htm 424B3 2642142
2 business10a.jpg GRAPHIC 134457
3 business11b.jpg GRAPHIC 660909
4 business12a.jpg GRAPHIC 290380
5 business13a.jpg GRAPHIC 132224
6 business14a.jpg GRAPHIC 55969
7 business15a.jpg GRAPHIC 55969
8 business17a.jpg GRAPHIC 65556
9 business18a.jpg GRAPHIC 268708
10 business1a.jpg GRAPHIC 128227
11 business2a.jpg GRAPHIC 68604
12 business3a.jpg GRAPHIC 65270
13 business4a.jpg GRAPHIC 76557
14 business5a.jpg GRAPHIC 60831
15 business6a.jpg GRAPHIC 283744
16 business7a.jpg GRAPHIC 73211
17 business8a.jpg GRAPHIC 65112
18 business9a.jpg GRAPHIC 90335
19 lenztherapeuticslogo1a.jpg GRAPHIC 208070
20 picture16.jpg GRAPHIC 30895
  Complete submission text file 0001628280-24-015671.txt   6492540
Mailing Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014
Business Address 445 MARINE VIEW AVE SUITE 320 DEL MAR CA 92014 858-925-7000
LENZ Therapeutics, Inc. (Filer) CIK: 0001815776 (see all company filings)

EIN.: 844867570 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 424B3 | Act: 33 | File No.: 333-278393 | Film No.: 24836880
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)